Results 151 to 160 of about 2,075,366 (204)
Some of the next articles are maybe not open access.
Abstract 4369443: ATTR-CM in the U.S.: Patterns of Healthcare Use and Medical Costs
CirculationObjective: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive heart disease caused by deposited amyloid fibrils, leading to stiffening of the heart muscle. Due to the absence of validated algorithms identifying ATTR-CM in claims data, limited evidence exists on healthcare resource utilization (HCRU)
Sodam Kim +3 more
openaire +2 more sources
Serum transthyretin in ATTR-CM: A pragmatic biomarker edging toward prime time
European Journal of Internal MedicineAlberto Aimo +2 more
openaire +2 more sources
Regression of Myocardial Bone-Avid Tracer Uptake After ATTR-CM Disease-Modifying Therapy
JACC: Cardiovascular ImagingS. Dorbala
openaire +2 more sources
Promising results for CRISPR-based therapy in ATTR-CM
Medicom Conference Report AHA 2024Robert van den Heuvel
openaire +2 more sources
ATTR-CM: Spezifische Therapie lohnt sich in jedem Alter
MMW - Fortschritte der MedizinG. Springer
openaire +2 more sources
Im Netzwerk zur frühen ATTR-CM-Diagnose
MMW - Fortschritte der MedizinP. Grätzel von Grätz
openaire +2 more sources
The clinical significance of transthyretin gene variant homozygosity in variant ATTR-CM
European Heart Journal, 2023Abstract Background Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a progressive condition characterised by the infiltration of the myocardial extracellular space resulting in progressive heart failure and mortality.
Y Razvi +14 more
openaire +1 more source
Improving ATTR-CM Detection: Targeting Populations With the Greatest Need
Journal of Cardiac FailureJOBAN VAISHNAV, KEVIN M. ALEXANDER
openaire +2 more sources
Consistent results for nexiguran ziclumeran across wildtype and variant ATTR-CM
Medicom Conference Report HFA 2025Robert van den Heuvel
openaire +2 more sources